Literature DB >> 27552060

Effects of long-term administration of pantoprazole on bone mineral density in young male rats.

Agnieszka Matuszewska1, Beata Nowak2, Marta Rzeszutko3, Krzysztof Zduniak3, Marta Szandruk1, Diana Jędrzejuk4, Marcin Landwójtowicz4, Marek Bolanowski4, Małgorzata Pieśniewska1, Joanna Kwiatkowska1, Adam Szeląg1.   

Abstract

BACKGROUND: Epidemiological studies suggest that long-term administration of proton pump inhibitors (PPIs) may decrease bone mineral density (BMD) and increase the risk of osteoporotic fractures. The aim of the study was to assess the influence of pantoprazole on bone metabolism in growing rats.
METHODS: The experiment was carried out on twenty-four young male Wistar rats divided into two groups receiving either pantoprazole at the dose of 3mg/kg or vehicle for 12 weeks. Femoral bone mineral density (BMD) and bone histomorphometry were assessed. Serum total calcium, inorganic phosphate and markers of bone turnover were measured.
RESULTS: In pantoprazole-treated rats a decreased BMD was detected (0.2618±0.0133g/cm(2)vs. 0.2715±0.0073g/cm(2), p<0.05). Bone histomorphometry revealed a decrease in growth plate thickness (G.Pl.RTh.) (161.0±27.8μm vs. 195.0±20.8, p<0.05) in pantoprazole-treated animals. Serum total calcium level and osteocalcin concentrations were decreased in the pantoprazole-treated group (9.62±0.55mg/dl vs. 10.15±0.38mg/dl, p<0.05 and 242.7±44.4pg/ml vs. 342.5±123.3pg/ml, p<0.05, respectively).
CONCLUSION: We observed that PPIs might have a negative impact on bone formation in growing rats mainly due to their inhibitory effects on the gastric proton pump, with probable deterioration of calcium absorption and decrease in growth plate thickness.
Copyright © 2016. Published by Elsevier Urban & Partner Sp. z o.o.

Entities:  

Keywords:  Bone metabolism; Bone mineral density; Calcium; Pantoprazole; Rats

Mesh:

Substances:

Year:  2016        PMID: 27552060     DOI: 10.1016/j.pharep.2016.06.012

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.

Authors:  Bhargavi V Desai; Misbah N Qadri; Bhavin A Vyas
Journal:  Eur J Clin Pharmacol       Date:  2021-10-29       Impact factor: 2.953

2.  Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease.

Authors:  Hussam Murad; Misbahuddin Rafeeq; Mahmoud Mosli; Mamdouh Gari; Mohammed Basheikh
Journal:  J Int Med Res       Date:  2021-11       Impact factor: 1.671

3.  Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.

Authors:  Ziping Cheng; Yangjie Liu; Mengyuan Ma; Shiyu Sun; Zengqing Ma; Yu Wang; Liyuan Yu; Xuping Qian; Luning Sun; Xuehui Zhang; Yun Liu; Yongqing Wang
Journal:  Mol Med       Date:  2022-02-19       Impact factor: 6.354

Review 4.  Proton Pump Inhibitors and Bone Health: An Update Narrative Review.

Authors:  Eric Lespessailles; Hechmi Toumi
Journal:  Int J Mol Sci       Date:  2022-09-14       Impact factor: 6.208

5.  Effects of Calcium and Annatto Tocotrienol Supplementation on Bone Loss Induced by Pantoprazole in Male Rats.

Authors:  Kok-Yong Chin; Benjamin Ka Seng Thong; Rhivaldy Faahim Kamalulloh; Nur Vaizura Mohamad; Sok Kuan Wong; Azlan Mohd Arlamsyah; Rahma Triliana; Ima Nirwana Soelaiman
Journal:  Drug Des Devel Ther       Date:  2020-07-02       Impact factor: 4.162

Review 6.  Role of Helicobacter pylori infection in the manifestation of old age-related diseases.

Authors:  Abolfazl Zendehdel; Maryam Roham
Journal:  Mol Genet Genomic Med       Date:  2020-02-17       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.